A comprehensive PolitiFact fact-check published July 1, 2026, has examined the compassionate use (expanded access) pathway that allowed an unapproved weight-loss drug — retatrutide — to reach patients before formal FDA approval, raising questions about whether an obesity medication is an appropriate candidate for a program designed for life-threatening conditions.
What Is Compassionate Use?
Compassionate use, formally known as expanded access, is an FDA program that allows patients with serious or immediately life-threatening diseases to access investigational drugs outside of clinical trials when no comparable alternative therapy exists. It is typically reserved for conditions like advanced cancer, ALS, or rare genetic disorders — situations where the potential benefit of an unproven treatment may outweigh the risks.
The program requires the drug manufacturer’s agreement, FDA authorization, and evidence that the patient’s condition has no satisfactory treatment alternative. It is not designed for elective or lifestyle-related conditions.
The Retatrutide Case
PolitiFact’s investigation centered on the revelation — first reported by STAT News and later confirmed through White House denials — that at least one patient identified via motorcade records as former President Donald Trump received retatrutide through expanded access. Retatrutide (developed by Eli Lilly) is a triple agonist targeting GIP, GLP-1, and glucagon receptors that has shown remarkable efficacy in clinical trials — including 30.3% mean weight loss in the TRIUMPH-1 Phase 3 study.
But retatrutide is being studied primarily for obesity and overweight, not for any life-threatening condition. PolitiFact interviewed multiple bioethicists and regulatory experts who questioned whether expanded access was the appropriate channel for a weight-loss drug.
Key Findings from the Fact-Check
No evidence of life-threatening indication: PolitiFact found no evidence that retatrutide is being researched as a treatment for any immediately life-threatening disease. Its primary indications in clinical trials are obesity, type 2 diabetes, osteoarthritis, and obstructive sleep apnea — all serious conditions, but none typically classified as immediately life-threatening.
Expanded access is a narrow pathway: The FDA’s expanded access rules require that the patient’s condition has no satisfactory alternative treatment. For obesity, multiple approved therapies exist — including semaglutide (Wegovy), tirzepatide (Zepbound), and lifestyle interventions — which could complicate the justification for expanded access.
Manufacturer discretion: Drug companies retain significant discretion over expanded access requests. Eli Lilly would have had to agree to supply retatrutide for any compassionate use request. The company has not publicly commented on whether it approved the specific request linked to former President Trump.
White House denial: Following the STAT News report, the White House denied that Trump was involved in seeking out or obtaining the drug through any special channel. The denial did not address whether the former president received the drug through standard expanded access procedures available to any qualifying patient.
Bioethicists Raise Concerns
PolitiFact quoted bioethicists who pointed out several concerns with using expanded access for an obesity drug:
- Equity: Compassionate use is available primarily to patients with connections to drug companies or prominent physicians, creating a two-tiered system of access.
- Precedent: Approving expanded access for a weight-loss drug could set a precedent for other lifestyle or quality-of-life medications.
- Data collection: Expanded access patients do not contribute to clinical trial data, meaning their experience does not advance scientific knowledge.
- Safety monitoring: Patients outside clinical trials may not receive the same level of safety monitoring as trial participants.
Canadian Context
While the expanded access controversy has unfolded in the United States, it carries implications for Canadian patients and regulators. Health Canada maintains its own Special Access Programme (SAP) for drugs not yet approved for sale in Canada. Unlike the U.S. expanded access pathway, Canada’s SAP has historically been used more restrictively — primarily for immediately life-threatening conditions.
For Canadians watching the retatrutide story, the key question is whether the drug’s approval timeline — expected following the completion of ongoing Phase 3 cardiovascular outcomes and safety trials — could be affected by the expanded access controversy. Regulatory experts suggest Eli Lilly’s FDA application timeline is unlikely to be impacted, as expanded access cases are administratively separate from the formal drug approval process.
The PolitiFact analysis also highlighted that in Canada, as in the U.S., there is no formal mechanism for public disclosure of expanded access recipients, raising transparency questions for patient advocates on both sides of the border.
What’s Next
Retatrutide remains in clinical trials for obesity and related conditions. Eli Lilly has not announced a specific submission date for FDA approval, though analysts widely expect a New Drug Application in late 2026 or early 2027, contingent on cardiovascular outcomes data.
The PolitiFact fact-check serves as a reminder that the expanded access pathway — a valuable tool for patients with life-threatening diseases — may be subject to misuse when applied to conditions where approved alternatives already exist. The piece urges regulators and drug companies to clarify the boundaries of compassionate use programs going forward.
Sources: PolitiFact (“A Primer on Retatrutide and Compassionate Use,” July 1, 2026); STAT News; FDA Expanded Access (Compassionate Use) guidance; Health Canada Special Access Programme documentation.